Who makes AND017 multiple dose?

AND017 multiple dose is developed by Kind Pharmaceuticals LLC.

What development phase is AND017 multiple dose in?

AND017 multiple dose is in Phase 1.

Last reviewed 2026-04-23 · How we verify

AND017 multiple dose

Kind Pharmaceuticals LLC · Phase 1 active Small molecule

At a glance

Generic name	AND017 multiple dose
Sponsor	Kind Pharmaceuticals LLC
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia (PHASE3)
A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PHASE3)
A Dose-escalation Study of AND017 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AND017 multiple dose CI brief — competitive landscape report
AND017 multiple dose updates RSS · CI watch RSS
Kind Pharmaceuticals LLC portfolio CI